Analyst picks & changes

Company

Bank

Analyst

Coverage

Opinion

Wk chg

6/27 cls

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)

Wells Fargo

Brian Abrahams

Upgrade

Outperform (from market perform)

6%

$12.52

Abrahams also increased his target to $17-$19 from $8-$9 after discussions with key opinion leaders suggest the current valuation does not fully reflect the likelihood of success and long-term opportunity for BCX4161 to treat hereditary angioedema (HAE). In late May, BioCryst reported that the selective inhibitor of plasma kallikrein that subsequently suppresses bradykinin production met the primary endpoint in a Phase IIa trial to treat HAE. Abrahams estimates $385M in 2025 U.S. sales.